Seeking Alpha

Curis (CRIS +0.3%) says it's licensed from Roche (RHHBY.PK) subsidiary Genentech, exclusive,...

Curis (CRIS +0.3%) says it's licensed from Roche (RHHBY.PK) subsidiary Genentech, exclusive, worldwide rights for the development and commercialization of GDC-0917, a small molecule that is designed to promote cancer cell death by antagonizing inhibitor of apoptosis (IAP) proteins. Additionally, the company says it's obtained $30M in secured debt financing to fund the development of its pipeline.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector